# GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

> **NCT03576612** · PHASE1 · COMPLETED · sponsor: **Candel Therapeutics, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Glioma, Malignant

## Interventions

- **BIOLOGICAL:** AdV-tk
- **DRUG:** Valacyclovir
- **RADIATION:** Radiation
- **DRUG:** Temozolomide
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03576612
- **Lead sponsor:** Candel Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-27
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-02-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03576612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03576612, "GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03576612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*